MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Medical Devices & Technology (Technology)
FDA _ Breakthrough Devices Program
2020: ArcherDX, Geneoscopy, Phagenesis win FDA breakthrough device designations
Attachments
ArcherDX, Geneoscopy, Phagenesis win breakthrough device designations | MedTech Dive
Parents
FDA _ Breakthrough Devices Program
Children
*By tracking RNA biomarkers, Geneoscopy thinks it can identify changes that occur downstream of cancer-causing DNA mutations, enabling it to detect tumors early.
*Geneoscopy is developing a colorectal cancer screening test.
*The test is underpinned by a method for extracting stool-derived eukaryotic RNA transcripts.
After inking a deal with Illumina ArcherDX detailed plans to seek approval for the product.
ArcherDX
ArcherDX is working on a test designed to enable timely therapeutic interventions for people with cancer.
Dubbed Personalized Cancer Monitoring, the company describes its technology as a way to “enable local labs to assess therapy success and identify disease recurrence much earlier than current standard of care such as imaging or antigen test modalities
GENEOSCOPY, INC.
Making successful treatment more likely.
Phagenesis